Previous concerns regarding the combined use of LMWH and GP IIb/IIIa antagonists (Braunwald et al., 2000)have been allayed byresults of recent trialsin which enoxaparin and UFH were compared in tirofiban-treated patients with UA/NSTEMI. In one study, the two anti-coagulants resulted in similar rates of major and minor bleeding (Cohen et al., 2002). Separate studies showed that the combined use of LMWH and GP IIb/IIIa antago-nists did not increase the risk of bleeding, even among patients undergoing PCI (Kereiakes et al., 2001; Young, Kereiakes, & Grines, 2000). Summaries of the ACC/AHA recommendations for antiplatelet and anticoagulant ther-apy are shown in Figure 1.